Core Insights - The company reported a revenue of approximately RMB 7,580.7 million for the six months ending June 30, 2025, representing a 15.9% increase compared to approximately RMB 6,542.7 million for the same period in 2024 [1] - The profit attributable to ordinary shareholders for the same period was approximately RMB 1,228.1 million, an 8.0% increase from approximately RMB 1,137.2 million in 2024 [1] Financial Performance - Total assets as of June 30, 2025, were approximately RMB 85,716.6 million, a decrease of 0.4% from approximately RMB 86,032.3 million as of December 31, 2024 [1] - Equity attributable to ordinary shareholders was approximately RMB 17,703.4 million as of June 30, 2025, reflecting a 3.1% increase from approximately RMB 17,175.7 million as of December 31, 2024 [1] - Return on equity for the six months ending June 30, 2025, was 14.08% [1] - Return on total assets for the same period was 3.11% [1]

Core Insights - The company reported a revenue of RMB 7.581 billion for the six months ending June 30, 2025, representing a year-on-year growth of 15.9% [1] - The profit attributable to ordinary shareholders was approximately RMB 1.228 billion, reflecting an 8% increase compared to the previous period [1] - Basic earnings per share stood at RMB 0.65 [1] Business Operations - As of June 30, 2025, the company operated 68 comprehensive and specialized medical institutions, providing quality medical services to the public [1] - The company engaged in full-cycle management of medical equipment and health technology businesses, including smart health and wellness services [1] - It offered comprehensive financial solutions centered around financing leasing for its clients [1]

Core Viewpoint - The company, Universal Medical (02666), reported a revenue of RMB 7.581 billion for the six months ending June 30, 2025, representing a year-on-year growth of 15.9% [1] - The profit attributable to ordinary shareholders was approximately RMB 1.228 billion, reflecting an 8% increase compared to the previous year [1] - Basic earnings per share were reported at RMB 0.65 [1] Group 1 - The company operates 68 comprehensive and specialized medical institutions, providing quality medical services to the public [1] - The company is engaged in full-cycle management of medical equipment and health technology businesses, including smart health and wellness services [1] - The company offers comprehensive financial solutions centered around financing leasing for its clients [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號：2666） 截至2025年6月30日止六個月的中期業績 財務摘要 1 • 截至2025年6月30日止六個月，收入約人民幣7,580.7百萬元，較2024年同期的約 人民幣6,542.7百萬元增長15.9%。 • 截至2025年6月30日止六個月，期內溢利約人民幣1,335.2百萬元，較2024年同期 的約人民幣1,252.2百萬元增長6.6%。 • 截至2025年6月30日止六個月，本公司普通股權益持有人應佔期內溢利約人民幣 1,228.1百萬元，較2024年同期的約人民幣1,137.2百萬元增長8.0%。 • 於2025年6月30日，總資產約人民幣85,716.6百萬元，較於2024年12月31日的約 人民幣86,032.3百萬元減少0. ...

Core Viewpoint - Global Medical (02666) has successfully issued the second tranche of notes by China Global Leasing Co., Ltd., amounting to RMB 500 million, with a fixed interest rate of 2.29% and a maturity of three years starting from August 25, 2025 [1] Summary by Relevant Categories Issuance Details - The actual issuance amount of the second tranche of notes is RMB 500 million [1] - The notes will mature in three years from August 25, 2025 [1] - The fixed interest rate for the notes is set at 2.29% [1] - The issuance price is RMB 100.0 per note, equivalent to the face value of the notes [1]

Core Viewpoint - Global Medical (02666.HK) announced the issuance of domestic medium-term notes with a total principal amount of up to RMB 500 million for the second phase in 2025 [1] Group 1 - The second phase of the notes was issued on August 22, 2025, in China, with an actual issuance amount of RMB 500 million [1] - The notes will mature in three years from August 25, 2025, with a fixed interest rate of 2.29% [1] - The issuance price for each note is RMB 100.0, which is equivalent to 100% of the face value of the notes [1]

智通财经APP讯，环球医疗(02666)公布，中国环球租赁有限公司第二期票据已于2025年8月22日在中国 完成发行，实际发行金额为人民币 5 亿元。第二期票据自2025年8月25日起计三年到期，固定利率为 2.29%，发行价格为每一票据人民币 100.0 元，发行价格等值于第二期票据面值的100%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號：2666） 1 本公司欣然宣佈第二期票據已於二零二五年八月二十二日在中國完成發行，實際發行金額為 人民幣 5 億元。第二期票據自二零二五年八月二十五日起計三年到期，固定利率為 2.29%， 發行價格為每一票據人民幣 100.0 元，發行價格等值於第二期票據面值的 100%。 承董事會命 通用環球醫療集團有限公司 本公司全資附屬公司中國環球租賃有限公司 完成第二期境內中期票據發行 本公告乃由通用環球醫療集團有限公司（「本公司」）根據香港聯合交易所有限公司證券上 市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章證券及期貨條例第XIVA部內幕 消息條文（定義見上市規則）作出。 茲提述本公司於二零二五年八月二十日刊發的公告（「該公告」），內容有關本公司的 ...

Group 1 - The company, Global Medical (02666), announced that its wholly-owned subsidiary, China Global Leasing Co., Ltd., plans to issue a total principal amount of up to RMB 500 million in the second phase of domestic medium-term notes for 2025 [1] - The second phase of the notes will have a term of three years and will feature a fixed interest rate, with the final rate to be determined through a book-building process at the time of subscription [1] - The net proceeds from the issuance of the second phase notes will be used by the issuer to repay maturing debts [1]

智通财经APP讯，环球医疗(02666)公布，公司的全资附属公司中国环球租赁有限公司已决定向中国境内 的机构投资者发行本金总额最高达人民币5 亿元的2025年第二期境内中期票据，第二期票据为期三年， 利率为固定利率，并将于截止认购申请时通过簿记建档方式最终厘定。发行第二期票据的净额收益将由 发行人用作偿还到期债务。 ...